Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies. - Ferrari M; Righi M; Baldan V; Wawrzyniecka P; Bulek A; Kinna A; Ma B; Bughda R; Akbar Z; Srivastava S; Gannon I; Robson M; et al. (Nature communications, 2024)